Buy Stoke (STOK) — Play the NDA/Advancement Rally; mid-term swing into the 52-week high
Stoke Therapeutics looks buyable here on a mid-term swing basis. The setup combines improving clinical readouts, a concentrated short base, and technical momentum around $32.05. Valuation is aggressive but event-driven upside and a high short-interest backdrop make a disciplined long trade attractive for the next 45 trading days.